Osteoclasts are the only cell type capable of resorbing mineralized bone, and they act under the control of numerous cytokines produced by supporting cells such as osteoblasts and stromal cells. Among cytokines, receptor activator of nuclear factor-kB ligand (RANKL) was found to be a key osteoclastogenetic molecule that directly binds to its cognate receptor, RANK, on osteoclast precursor cells. In turn, RANKL, which is an essential factor for differentiation and activation of osteoclasts, is one of the major targets of anti-resorptive agents. In this study, we found that palmatine, an isoquinoline alkaloid originally isolated from Coptis chinensis, had an inhibitory effect on osteoclast differentiation and function in vitro. Palmatine inhibited osteoclast formation in the co-culture system with mouse bone marrow cells (BMC) and osteoblasts in the presence of 10 nM 1a,25-(OH) 2 D 3 . Palmatine did not affect osteoclast formation induced by RANKL in the BMC cultures. Reverse-transcription polymerase chain reaction (RT-PCR) analysis showed that palmatine significantly inhibited the expression of 1a,25-(OH) 2 D 3 -induced expression of RANKL mRNAs in stromal cells without loss of cell viability. Moreover, palmatine suppressed resorption pit formation by mature osteoclasts on dentin slices and induced disruption of actin ring formation in mature osteoclasts with an impact on cell viability. Taken together, these results suggest that palmatine attenuates osteoclast differentiation through inhibition of RANKL expression in osteoblast cells, and its inhibitory effect on bone resorption is due to its disruptive effect on actin rings in mature osteoclasts. Therefore, palmatine might be an ideal candidate as an anti-resorptive agent for the prevention and treatment of bone disorders such as osteoporosis.
Osteoclasts, multinucleated cells responsible for bone resorption, develop from hemopoietic cells of the monocytemacrophage lineage under the control of the bone microenvironment. [1] [2] [3] [4] A coculture system of mouse osteoblasts and hemopoietic cells was developed to examine the regulatory mechanisms of osteoclast differentiation and function. 5, 6) A series of experiments using the coculture system have shown that osteoblasts are critically involved in osteoclast development. 7, 8) Receptor activator of nuclear factor-kB ligand (RANKL) is a member of the tumor necrosis factor (TNF) superfamily that is expressed in osteoblasts. 9) It interacts with the osteoclast cell surface receptor RANK, which in turn recruits TNFR-associated factors (TRAFs), 10, 11) and induces the differentiation of osteoclast precursors into osteoclasts. Osteoblasts also produce osteoprotegerin (OPG), a decoy receptor for RANKL, to inhibit osteoclast function.
12) The RANKL: RANK signaling pathway could be a major target of anti-resorptive agents.
Palmatine (molecular structure: inset of Fig. 1 ), a member of the protoberberine class of isoquinoline alkaloids, is a bioactive herbal ingredient isolated from Rhizoma coptidis, Cortex phellodendri, Radix tinosporae, and Enantia chlorantha. It is an important traditional medicinal herb which has been reported to be effective against experimental tumors by inhibiting the activity of reverse transcriptase. 13) In another study, palmatine was shown to possess antipyretic, antibacterial, antifungal, antivirus, antiphotooxidative, dispelling dampness, antidote, antinociceptive, and anti-inflammatory activities in vitro and in vivo. [14] [15] [16] [17] [18] [19] [20] [21] [22] In addition to its medicinal uses, palmatine is also used as a fluorescent probe of DNA, RNA, and enzymes in biochemical research. [23] [24] [25] [26] In spite of these broad uses, the effects of palmatine on osteoclastogenesis remain uncertain.
To discover new types of anti-resorptive agents, we screened for 60 commercial natural compounds isolated from medicinal plants. In our screening, we found that palmatine has a strong inhibitory effect on TRAP activity in osteoclast formation. In the present study, we showed that palmatine inhibited osteoclast differentiation through inhibition of RANKL expression in osteoblastic cells and suppressed osteoclast differentiation by inducing the disruption of actin rings in mature osteoclasts.
MATERIALS AND METHODS

Reagents
Male Std ddY mice (6-9 weeks of age) were purchased from Japan SLC Co. (Hamamatsu, Japan). The animal protocols and procedures used in this study were approved by the Institutional Animal Care and Use Committee of Chubu University. Recombinant soluble RANKL (sRANKL) was purchased from PeproTech EC Ltd. (London, U.K. (Nagoya, Japan). Alexa Fluor phalloidin was purchased from Invitrogen (CA, U.S.A.). All other chemicals and reagents were of analytical grade. Cell Culture The murine macrophage cell line RAW264.7 and mouse clonal stromal cells from bone marrow (ST2) were obtained from the RIKEN Cell Bank (Tsukuba, Japan). The cells were maintained in a-minimum essential medium (a-MEM) containing 10% fetal bovine serum (FBS) (Sigma, St. Louis, MO, U.S.A.).
Cell Viability Assay Cell viability was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Bone marrow macrophages (BMMs) were cultured under the same conditions used for osteoclastogenesis experiments, and MTT reagent was added at 3 h before the end of the culture. The supernatants were carefully removed, dissolved in dimethylsulfoxide (DMSO) and their absorbance measured at 570 nm using a microplate reader.
Mouse BMMs and Co-cultures Bone marrow cells (BMCs) were obtained from the tibiae of 4-6-week-old ddY male mice. In the co-culture system. 6, 27) BMCs were co-cultured with ST2 cells on 24-well plates in the presence of 10 nM 1a,25-(OH) 2 D 3 for 5 d. After the co-culture, some of the cells were fixed and stained for tartrate-resistant acid phosphatase (TRAP), a marker enzyme for osteoclasts. To obtain mature osteoclasts, BMCs (1ϫ10 7 cells) and mouse stromal cell line ST2 cells (1ϫ10 6 cells) were co-cultured in collagen gel-coated 100-mm plates for 5-6 d in a-MEM containing 10% FBS, 10 nM 1a,25-(OH) 2 D 3 and 1 mM PGE 2 . The plates were treated with collagenase and whole cells were harvested for use in subsequent experiments.
Polymerase Chain Reaction (PCR) Amplification of Reverse-Transcribed mRNA For RT-PCR analyses, ST2 cells were cultured in a-MEM containing 10% FBS and 10 nM 1a,25-(OH) 2 D 3 in 60-mm dishes. After culture for 48 h, total cellular RNA was extracted from ST2 cells using TRIzol solution (Life Technologies Inc.). First-strand cDNA was synthesized from the total RNA with random primers and subjected to PCR amplification with Ex Taq polymerase (Takara Biochemicals, Shiga, Japan) using the following specific PCR primers: mouse RANKL, 5Ј-CGC TCT GTT CCT GTA CTT TCG AGC G-3Ј (forward) and 5Ј-TCG TGC TCC CTC CTT TCA TCA GGT T-3Ј (reverse); mouse OPG, 5Ј-TGG AGA TCG AAT TCT GCT TG-3Ј (forward) and 5Ј-TCA AGT GCT TGA GGG CAT AC-3Ј (reverse); mouse M-CSF, 5Ј-GAG AAG ACT GAT GGT ACA TCC-3Ј (forward) and 5Ј-CTA TAC TGG CAG TTC CAC C-3Ј (reverse); mouse GAPDH, 5Ј-ACC ACA GTC CAT GCC ATC AC-3Ј (forward) and 5Ј-TCC ACC ACC CTG TTG CTG TA-3Ј (reverse). The PCR products were separated by electrophoresis in 2% agarose gels and visualized by ethidium bromide staining under UV light illumination. The sizes of the PCR products for mouse RANKL, OPG, M-CSF and GAPDH were 587, 720, 516 and 452 bp, respectively.
Osteoclast Differentiation from Mouse BMMs To obtain BMMs, BMCs were cultured for 3 d in a-MEM containing 10% FBS and M-CSF (50 ng/ml) in 60-mm dishes. 6, 27) After culture for 1 d, non-attached cells in the culture plates were collected and used as BMMs. In the BMM culture system, BMMs were cultured in 96-well plates in the presence of M-CSF (50 ng/ml) for 3 d, treated with RANKL (100 ng/ml) and cultured for a further 3 d. The cells were then sequentially fixed with 10% formalin for 10 min and ethanol for 1 min, and dried. Measurement of TRAP activity and staining for TRAP were performed. TRAP-positive multinucleated cells containing more than 5 nuclei were counted.
Pit Formation and Actin Ring Formation Assays Mature osteoclasts were obtained from mouse cocultures on collagen gel-coated dishes as described above. For resorption pit assays, aliquots of the crude mature osteoclast preparations were placed on dentin slices in 96-well plates. 28) After preincubation for 2 h, the dentin slices were transferred to 48-well plates (1 dentin slice/well) containing 0.3 ml of a-MEM supplemented with 10% FBS, and further cultured with or without palmatine for 48 h. Resorption pits on the dentin slices were visualized by staining with hematoxylin. The number of resorption pits on each slice was counted. Actin rings of osteoclasts were detected by staining actin filaments with alexa phalloidin. Mature osteoclasts were placed on dentin slices under the same conditions as the pit formation assay. At the end of the incubation, osteoclasts were stained for TRAP activity and TRAP-positive osteoclasts were stained with alexa phalloidin in the dark. The distribution of actin rings was visualized and detected under a fluorescence microscope.
Caspase-3 Activity Mature osteoclasts were prepared from RAW264.7 cells in the presence of RANKL (50 ng/ml) and PD98059 (20 mM). (PD98059 is known to increase TRAP-positive cell formation induced by RANKL in RAW264.7 cell culture 29) ; thus we used PD98059 to rapidly prepare a high number of mature osteoclasts). Caspase activity was assayed using a fluorometric kit purchased from MBL Co., Ltd. In brief, the cells cultured with PD98059 and RANKL for 3 d and then the monocytes were washed out, leaving behind the multinucleated cells. The purified mature osteoclasts were treated with palmatine at 10, 20, 40 mM for 6 h. The cells were washed with ice-cold PBS and lysed in a cell lysis buffer (100 mM Tris/HCl, pH 7.5, 1 mM DTT, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride (PMSF) provided with the kit. The lysated cells were centrifuged for 15 min at 40000 g and the supernatant was collected for determination of the caspase-3 activity. The caspase-3 (DEVE-AMC) substrate was added to the cell lysates in a 96-well plate, and the plates were then incubated. The release of AMC was determined by measuring the fluorescence counts in the wells (380 nm excitation filter and 460 nm emission filter). The change in fluorescence was monitored for 90 min.
Statistical Analysis The data were expressed as the meanϮS.D. Statistical analyses were performed by an unpaired two-tailed Student's t-test assuming unequal variances. Values of pϽ0.01 were considered to indicate statistical significance. (Fig. 1B) . We found that palmatine (10-40 mM) dose-dependently decreased the numbers of TRAP-positive multinucleated osteoclasts. Complete inhibition of osteoclast formation was observed in the cocultures treated with palmatine at 40 mM. However, palmatine did not affect cell viability of osteoblastic cells and BMCs, as detected by the MTT assay (data not shown).
RESULTS
Palmatine Inhibits Osteoclast
Palmatine Does Not Inhibit Osteoclast Formation in Bone Marrow Cell Cultures To determine the effects of palmatine on osteoclast formation from osteoclast progenitor cells in the absence of osteoblasts, mouse BMMs were incubated with palmatine in the presence of RANKL and M-CSF, and allowed to grow and differentiate into osteoclasts. As shown in Fig. 2C , RANKL dramatically induced osteoclast formation in BMMs. However, palmatine did not significantly inhibit osteoclast formation induced by RANKL at concentrations of 1-40 mM. As detected by the MTT assay, the viabilities of BMMs were decreased by palmatine at 40 mM concentration throughout the entire period of culture (Fig. 2B) . These results suggest that palmatine has no inhibitory effect on osteoclast precursor cells.
Palmatine Inhibits the Expression of RANKL Gene Induced by 1a,25-(OH) 2 D 3 in Osteoblastic Cells Next, we determined the effect of palmatine on osteoblastic ST2 cells to support osteoclast formation in the presence of 1a,25-(OH) 2 D 3 . ST2 cells were cultured with the increasing concentrations of palmatine and cell growth of ST2 was examined by the MTT assay (Fig. 3A) . The cell viability was not affected by palmatine at 40 mM. Next, we examined its effects on the expressions of RANKL, OPG and M-CSF in ST2 cells treated with 1a,25-(OH) 2 D 3 10 Ϫ8 M. Treatment of ST2 cells with 1a,25-(OH) 2 D 3 enhanced the expression of RANKL, suppressed the expression of OPG and sustained the expression of M-CSF. Palmatine had a suppressive effect on the upregulation of RANKL mRNA expression in a dosedependent manner but had no effects on the OPG and M-CSF mRNA expression levels (Fig. 3B) . These results suggest that inhibitory effect of palmatine on osteoclastogenesis was due to inhibition of the RANKL gene expression in osteoblasts not involved in osteoclast precursors.
Palmatine Suppresses Pit Formation on Bone Slices and Disrupts Actin Rings
To investigate the effects of palmatine on bone resorption function, we examined the effects of palmatine on the pit formation and actin rings of osteoclasts induced by 1a,25-(OH) 2 D 3 and PGE 2 in the mouse co-culture system. The method for pit-formation assay using dentine slices is common methods for investigating the function of mature ostoclasts. When osteoclasts are placed on dentine slices, they form resorption pits within 24 h in the presence of osteoblasts. Then the dentin slices were stained with hematoxylin to identify resortion pits. 6, 27) Osteoclasts formed by co-cultures with BMCs and ST2 cells readily created resorption pits on dentine slices. Palmatine inhibited pit formation on the dentin slices in a dose-dependent manner. At 40 mM, palmatine inhibited the pit formation by approximately 90% (Fig. 4A) . Actin ring formation in mature osteoclasts is essential for the expression of their bone resorption activity. Next, we examined the actin rings by staining with alexa phalloidin (Fig. 4B) . Alexa phalloidin is a high-affinity probe for F-actin and used to stain the osteoclast sealing zone. 30) When osteoclasts with actin rings were treated with palmatine for 24 h, the size was constricted and the actin rings were disrupted. These results indicate that the effect of palmatine on bone resorption is due to the disruption of the actin rings.
Palmatine Does Not Affect Cell Survival of Mature Osteoclasts in the Presence of Osteoblastic Cells Major cytoskeletal filaments, including actin, are degraded during the execution phase of apoptosis. 31, 32) Therefore we next determined whether the actin ring-disruptive effect of palmatine results from its proapoptotic effect in osteoclasts. Caspase-3 plays a central role in the execution phase of cell apoptosis. 33) Therefore, to pursue the potential influence of apoptosis on palmatine, caspase-3 activity in mature osteoclasts was determined. As shown in Fig. 5 , cycloheximide significantly increased caspase-3 activity by approximately 2-fold over the control level. And treatment of Z-DEVD-FMK, a specific caspase-3 inhibitor, was able to suppress the caspase-3 activity to the control level. However, palmatine failed to induce caspase-3 activity in mature osteoclasts even at 40 mM. These results suggest that the disruptive effect of palmatine on actin ring does not result from its proapoptic efffect on mature osteoclasts.
DISCUSSION
To discover new types of anti-resorptive agents, we screened for natural compounds that regulate osteoclast differentiation and function. Here we found that palmatine inhibits osteoclast differentiation in a co-culture system using osteoblasts and BMC. Palmatine also inhibited bone resorption on dentine slices by disrupting the cytoskeletal structure of the actin ring in mature osteoclasts in the presence of osteoblastic cells, without affecting cell survival. These inhibitory effects of palmatine on osteoclast differentiation and function may result from blocking the gene expression of RANKL in osteoblastic cells.
In mouse cell co-cultures, osteoclasts are formed in re- These pathways for RANKL gene expression could be one of the major targets of anti-resorptive agents. In this study, palmatine inhibited the expression of the RANKL gene in osteoblastic cells, but did not inhibit OPG and M-CSF expression. Dong et al., 35) reported that 3,3Ј-diindolmethane, one of the natural compounds formed during the autolysis of glucobrassicin, effectively inhibited the expression of RANKL in osteoblastic cells, leading to the blockade of osteoclastogenesis and consequently an alleviation of experimental arthritis.
Osteoclasts have unique properties for resorbing bone. The most characteristic features of osteoclasts are the presence of ruffled borders and sealing zones. 36, 37) The sealing zones serve to attach osteoclasts to the bone surface and isolate the resorption areas from the surrounding areas.
37) The sealing zone is defined as a unique large band of F-actin dots. [37] [38] [39] Sealing zone formation in osteoclast precedes the initiation of bone resorption. It has been reported that disruption of the sealing zones suppresses the bone-resorbing activities of osteoclasts. [40] [41] [42] In the present study, we have demonstrated that palmatine inhibits osteoclastic bone resorption by dis- The mature osteoclasts were cultured on dentin slices with increasing concentrations of palmatine. (A) After culture for 48 h, the cells were fixed with paraformaldehyde. After removal of the cells, the dentin slices were stained with Mayer's hematoxylin to identify resorption pits and pits were counted on dentin slice (right panels). (B) After culture for 48 h, the cells were fixed with paraformaldehyde, permeabilized with Triton X-100, and incubated with alexa-conjugated phalloidin. F-actin was detected using a fluorescence microscope. Actin rings were counted on dentin slice (right panels). The results are expressed as the meansϮS.D. of three cultures. * pϽ0.05. rupting actin rings. During the execution phase of apoptosis, cytoskeletal structure such as actin rings could be degraded. But palmatine did not induce apoptosis in purified mature osteoclasts prepared by BMCs. Therefore, the actin ring-disruptive effect of palmatine may not result from its proapoptotic effect. Because RANKL is also known to induce actin ring formation in mature osteoclasts, palmatine-induced inhibition of RANKL gene expression in osteoblastic cells could explain its disruptive effect of actin tings in osteoclasts. In our previous data showed that when mononuclear osteoclasts were cultured on the plates, which is not contaminated with multinucleated osteoclast and osteoblast cells, mononuclear osteoclasts were fused to multinucleated osteoclasts within 6 h in the presence of RANKL. 43) RANKL-induced multinucleated osteoclasts showed typical properties of osteoclasts such tartarate-resistant acid phosphatase (TRAP) activity, actin ring formation, and bone-resorbing activity. These results suggest that NF-kB activation is an important for all process for the survival and fusion of osteovclasts induced by osteoblast cells. Taken together, it seemed possible that this reduction of the mature bone resorbing activity is mediated through the suppression of RANKL expression in osteoblasts.
Palmatine (Fig. 1A) is a close structural analog of berberine. It bears the same tetracyclic structure (7, 8, 13 ,13a-tetrahydro-9,10-dimethoxy-berberinium) as berberine, but differs by the nature of the substituents at positions 2 and 3 on the benzo ring, being methylene dioxy for berberine and a dimethoxy for palmatine. Similar to berberine, palmatine also has a buckled structure. Recently, berberine has been reported to inhibit RANKL-induced osteoclast differentiation from osteoclast precursors, survival of mature osteoclasts and ovariectomy-stimulated bone resorption in rats. [44] [45] [46] Although there is close similarity between the structures of berberine and palmatine, berberine directly acts on both osteoclast precursors and mature osteoclasts, and then inhibits osteoclast differentiation and function. The inhibitory effects of berberine are mediated by blockage of RANKL-induced signaling pathways. However, in present study palmatine did not affect both RANKL-induced osteoclast differentiation from osteoclast precursors and RANKL-induced signaling pathways. Palmatine inhibited the expression of the RANKL gene in osteoblastic cells, and then attenuated osteoclast differentiation and function in cocultures. Structural differences, methylene dioxy for berberine and a dimethoxy for palmatine on the benzo ring may be responsible for the difference of their target cell for osteoclast differentiation.
Osteoclast formation can be inhibited by directly targeted osteoclast precursor as well as by indirectly co-cultured with osteoblastic/stromal cells. In this study, we have demonstrated that palmatine inhibit osteoclast formation by induced co-culture and resorbing activity of mature osteoclasts. These inhibitory effects of palmatine could be explained by its inhibition of RANKL gene expression in osteoblastic cells. Although the precise and detailed mechanism of palmatine inhibition remains to be scrutinized, we propose that palmatine might be useful as a potential therapeutic medication for attenuating osteoclast formation and function in the prevention and treatment of bone diseases such as osteoporosis.
